Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I Open-label Dose Escalation and Dose Expansion Study of CGX1321 in Patients With Advanced Solid Tumors and Phase Ib Study of CGX1321 in Combination With Pembrolizumab in Patients With Advanced Gastrointestinal Tumors

Summary

The purpose of this phase I trial is to evaluate the safety and feasibility of CGX1321 in patients with advanced solid tumors, including pancreatic adenocarcinoma. Note: This trial is currently enrolling patients into the dose escalation part of the study.

General Information

NCT#: NCT02675946
Study ID: CGX1321-101
Trial Phase: Phase I

Trial Sponsor: Merck Sharp & Dohme Corp., Curegenix Inc.
Therapies Used in This Trial: Pembrolizumab, CGX1321

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search